Amgen
ABOUT US
Amgen harnesses the best of biology and technology to make people's lives easier, fuller, and longer. We draw upon our deep knowledge of science to push beyond what's known today. With roots in the biotech revolution, we are one of the world's leading independent biotech companies - fighting the toughest diseases and helping millions of people globally.
1 Amgen Center Drive
Thousand Oaks, CA 91320
(703) 955-6090
amgen.com
PRIMARY CONTACTS
Keith Knowles
National Account Manager
(703) 955-6090
kknowles@amgen.com
Dan Flores, PharmD
Medical Value and Access Director
(973) 362-8300
danflore@amgen.com
PRODUCTS OR SERVICES
VENCLEXTA is a BCL-2 inhibitor indicated:
-
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
-
- In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
LUPRON DEPOT (leuprolide acetate for depot suspension):
-
- Is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostatic cancer.
PRODUCTS OR SERVICES
MVASI® (bevacizumab-awwb)
NEULASTA® (pegfilgrastim)
NEUPOGEN® (filgrastim)
NPLATE® (romiplostim)
OTEZLA® (apremilast)
PARSABIV® (etelcalcetide)
PROCYSBI® (crysteamine bitartrate)
PROLIA® (denosumab)
RAVICTI® (glycerol phenylbutryrate)
REPATHA® (evolocumab)
RIABNI® (rituximab-arrx)
SENSIPAR® (cinacalcet)
TAVNEOS® (avacopan)
TEZSPIRE® (tezepelumab-ekko)
VECTIBIX® (panitumumab)
XGEVA® (denosumab)